Transient Benefit in Outcomes Seen With Androgen Suppression + RT for Prostate Cancer
Transient clinically meaningful decline noted in EPIC hormonal and sexual domains with total androgen suppression added to radiation
Transient clinically meaningful decline noted in EPIC hormonal and sexual domains with total androgen suppression added to radiation
Emerging evidence links bladder cancer to pelvic radiation therapy, dietary factors, and gene-environment interactions.
Trimodality therapy produces similar oncologic outcomes as radical cystectomy in patients with muscle-invasive bladder cancer, a new study suggests.
NRG 0815 is a “landmark” study investigating the role of short-term androgen deprivation therapy added to modern, dose-escalated radiation to treat intermediate-risk prostate cancer.
An updated systematic review of 50 studies supports the use of cranberry products in reducing the risk for urinary tract infections.
Finding is based on a meta-analysis of 14 high-quality studies involving 19,365 patients.
Similar radiotherapy schedules seen for patients with and without psychiatric disorder, but overall survival worse for those with psychiatric illness
Renal function declines slightly in the first year of follow-up and then remains stable through 10 years.
Cardiovascular disease is a leading cause of noncancer death in men with prostate cancer.
The risk for biochemical recurrence of prostate cancer after external beam radiation therapy varies by prostate cancer risk category.